AtriCure, Inc.
ATRC
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $2.6B
$51.52
▼ -1.79%
P/E
231.86
Mkt Cap
$2.6B
52-Wk Range
$25.36–$53.50
52-Week Range
$25.36 - $53.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive product portfolio addressing multiple surgical approaches to atrial fibrillation treatment
- Strong intellectual property and regulatory approvals (FDA clearances and CE marks)
- Established relationships with cardiac surgeons and direct sales force in key markets
- Innovative multifunctional devices that reduce procedure complexity and improve surgeon efficiency
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Stable outlook
Rising prevalence of atrial fibrillation and increasing demand for surgical ablation procedures
Value
Extreme premium - high expectations embedded
Momentum
Hot
+91.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying ATRC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 23, 2026
Reported EPS of $0.18 vs -$0.00 consensus (+10878.4% surprise). Revenue of $153.6M vs $151.8M expected (+1.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+10878.4%
Revenue trend · last 8Q
—
+17%
+14%
+17%
+16%
+13%
+14%
+13%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$115.9M
$124.3M
$123.6M
$136.1M
$134.3M
$140.5M
$141.2M
$153.6M
Margins · last 8Q
Gross
77.2%
Operating
6.3%
Profit
5.8%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Needham · Sep 2, 2026
vs Industry
How ATRC stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related